Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Venous Thromboembolism Market Size, Value And Growth Trends Through 2030
The market for venous thromboembolism treatments has experienced consistent expansion, projecting a rise from $2.53 billion in 2025 to $2.63 billion in 2026, signifying a compound annual growth rate of 3.9%. This historical growth trajectory is underpinned by several key factors, including a greater incidence of venous thromboembolism cases, an expanding elderly demographic, the increasing prevalence of sedentary habits among the population, enhanced clinical recognition of VTE-related risks, and a broader availability of hospital-based care for thrombotic conditions.
The market for venous thromboembolism is projected to experience consistent expansion, reaching an estimated $3.2 billion by the year 2030 with a compound annual growth rate of 5.0%. This anticipated growth throughout the forecast period is bolstered by several key factors, including a greater embrace of individualized anticoagulant therapies, a heightened demand for less invasive treatment approaches, the proliferation of outpatient VTE care frameworks, increased financial input into sophisticated diagnostic technologies, and a heightened emphasis on proactive thrombosis management. Furthermore, prevailing trends shaping this market during the forecast period encompass the growing utilization of newer oral anticoagulants, a rise in the application of mechanical thrombectomy devices, an intensifying focus on prompt diagnosis and accurate risk assessment, the broad adoption of home-based VTE management initiatives, and enhancements in the oversight of anticoagulant treatments.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp
Venous Thromboembolism Market Growth Factors: Which Forces Are Supporting Market Expansion?
An expanding healthcare infrastructure is anticipated to be a key factor driving the venous thromboembolism market’s advancement. The healthcare sector encompasses the integration and consolidation of various economic segments that supply goods and services aimed at patient treatment, prevention of illness, rehabilitation, and end-of-life care. This burgeoning healthcare industry fosters the development of institutional frameworks, policies, practices, and educational initiatives essential for putting VTE prevention strategies into action. For example, data from May 2023, courtesy of the American Health Care Association, a non-profit entity in the US, revealed a rise in the nation’s hospital count to 6,129, up from 6,093 in the preceding year, thereby underscoring the trajectory of healthcare industry expansion as a catalyst for the venous thromboembolism market’s growth.
A surge in orthopedic surgical interventions is projected to fuel the expansion of the venous thromboembolism market. Orthopedic surgeries encompass procedures designed to address spinal and joint ailments, as well as correct skeletal deformities. Interventions like total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) carry a significant risk of VTE, leading to a greater utilization of compression devices for deep vein thrombosis (DVT) prevention. These compression devices are employed to impede the formation of blood clots within the deep leg veins, a primary cause of venous thromboembolism (VTE). Specifically, research published in February 2023 by the National Library of Medicine, a US-based biomedical resource, projected that THA and TKA procedures would see an increase to 719,364 and 1,222,988 respectively by 2040, with TKAs expected to reach 2,917,959 and THAs 1,982,099 by 2060, illustrating how the growing volume of orthopedic surgeries is stimulating the venous thromboembolism market.
Venous Thromboembolism Market Segmentation And Category Breakdown
The venous thromboembolism market covered in this report is segmented –
1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types
2) By Treatment: Anti-Clotting Medications, Mechanical Devices, Thrombolytic Therapy, Other Treatment
3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users
Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE
3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome
Venous Thromboembolism Market Industry Trends: What Changes Are Reshaping Demand?
Within the venous thromboembolism (VTE) market, leading entities are prioritizing the integration of cutting-edge vascular-access sheath innovations, notably laser-cut hypotube sheaths, aiming to elevate operational efficiency, bolster patient safety, and refine procedural discretion. This advanced technology involves a slender, metallic tubing that undergoes precise laser cutting to form a sheath offering a blend of flexibility and robust structural integrity, thereby facilitating effortless navigation within vascular pathways, providing steady reinforcement during catheter insertion, and ensuring superior control over bleeding during medical procedures. Illustratively, Penumbra Inc., a prominent US medical device firm, unveiled the Element Vascular Access System in January 2025; this system, engineered for VTE interventions, incorporates a laser-cut hypotube sheath equipped with the HemoLock dual-valve mechanism for meticulous hemostasis management, alongside an atraumatic tip and substantial 17 F MaxID dimensions to ensure seamless insertion and accommodate large-bore thrombectomy apparatus. The Element system is poised to augment procedural speed, improve device maneuverability, and grant clinicians greater command, ultimately contributing to enhanced safety and more favorable results in VTE treatments.
Venous Thromboembolism Market Competitive Analysis Of Major Industry Participants
Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co Inc, AbbVie Inc, Bayer AG, Novartis AG, Sanofi-Aventis LLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Co Ltd, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Company Limited, Portola Pharmaceuticals Inc, Viatris Inc, AstraZeneca PLC, Medtronic plc, Boston Scientific Corporation, Stryker Corporation, Abbott Laboratories, AngioDynamics Inc, Terumo Corporation
Access The Complete Venous Thromboembolism Market Report:
https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report
Venous Thromboembolism Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the venous thromboembolism market in 2025. The regions covered in the venous thromboembolism market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
